Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.
There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation mo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Castle, Philip E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Impaired central coherence in patients with anorexia nervosa - Hamatani, Sayo ELSEVIER, 2017, an international journal devoted to practice and theory, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:111 ; year:2018 ; pages:177-179 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ypmed.2018.03.011 |
|---|
| Katalog-ID: |
ELV042863112 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042863112 | ||
| 003 | DE-627 | ||
| 005 | 20230626002530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ypmed.2018.03.011 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica |
| 035 | |a (DE-627)ELV042863112 | ||
| 035 | |a (ELSEVIER)S0091-7435(18)30100-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.91 |2 bkl | ||
| 100 | 1 | |a Castle, Philip E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. | ||
| 520 | |a There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. | ||
| 700 | 1 | |a Wheeler, Cosette M. |4 oth | |
| 700 | 1 | |a Campos, Nicole G. |4 oth | |
| 700 | 1 | |a Sy, Stephen |4 oth | |
| 700 | 1 | |a Burger, Emily A. |4 oth | |
| 700 | 1 | |a Kim, Jane J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Hamatani, Sayo ELSEVIER |t Impaired central coherence in patients with anorexia nervosa |d 2017 |d an international journal devoted to practice and theory |g Amsterdam |w (DE-627)ELV000729329 |
| 773 | 1 | 8 | |g volume:111 |g year:2018 |g pages:177-179 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ypmed.2018.03.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.91 |j Psychiatrie |j Psychopathologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 111 |j 2018 |h 177-179 |g 3 | ||
| author_variant |
p e c pe pec |
|---|---|
| matchkey_str |
castlephilipewheelercosettemcamposnicole:2018----:nfiinisfvrcennadnesreigocriacn |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
44.91 |
| publishDate |
2018 |
| allfields |
10.1016/j.ypmed.2018.03.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica (DE-627)ELV042863112 (ELSEVIER)S0091-7435(18)30100-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.91 bkl Castle, Philip E. verfasserin aut Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. 2018transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. Wheeler, Cosette M. oth Campos, Nicole G. oth Sy, Stephen oth Burger, Emily A. oth Kim, Jane J. oth Enthalten in Elsevier Hamatani, Sayo ELSEVIER Impaired central coherence in patients with anorexia nervosa 2017 an international journal devoted to practice and theory Amsterdam (DE-627)ELV000729329 volume:111 year:2018 pages:177-179 extent:3 https://doi.org/10.1016/j.ypmed.2018.03.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.91 Psychiatrie Psychopathologie VZ AR 111 2018 177-179 3 |
| spelling |
10.1016/j.ypmed.2018.03.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica (DE-627)ELV042863112 (ELSEVIER)S0091-7435(18)30100-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.91 bkl Castle, Philip E. verfasserin aut Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. 2018transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. Wheeler, Cosette M. oth Campos, Nicole G. oth Sy, Stephen oth Burger, Emily A. oth Kim, Jane J. oth Enthalten in Elsevier Hamatani, Sayo ELSEVIER Impaired central coherence in patients with anorexia nervosa 2017 an international journal devoted to practice and theory Amsterdam (DE-627)ELV000729329 volume:111 year:2018 pages:177-179 extent:3 https://doi.org/10.1016/j.ypmed.2018.03.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.91 Psychiatrie Psychopathologie VZ AR 111 2018 177-179 3 |
| allfields_unstemmed |
10.1016/j.ypmed.2018.03.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica (DE-627)ELV042863112 (ELSEVIER)S0091-7435(18)30100-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.91 bkl Castle, Philip E. verfasserin aut Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. 2018transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. Wheeler, Cosette M. oth Campos, Nicole G. oth Sy, Stephen oth Burger, Emily A. oth Kim, Jane J. oth Enthalten in Elsevier Hamatani, Sayo ELSEVIER Impaired central coherence in patients with anorexia nervosa 2017 an international journal devoted to practice and theory Amsterdam (DE-627)ELV000729329 volume:111 year:2018 pages:177-179 extent:3 https://doi.org/10.1016/j.ypmed.2018.03.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.91 Psychiatrie Psychopathologie VZ AR 111 2018 177-179 3 |
| allfieldsGer |
10.1016/j.ypmed.2018.03.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica (DE-627)ELV042863112 (ELSEVIER)S0091-7435(18)30100-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.91 bkl Castle, Philip E. verfasserin aut Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. 2018transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. Wheeler, Cosette M. oth Campos, Nicole G. oth Sy, Stephen oth Burger, Emily A. oth Kim, Jane J. oth Enthalten in Elsevier Hamatani, Sayo ELSEVIER Impaired central coherence in patients with anorexia nervosa 2017 an international journal devoted to practice and theory Amsterdam (DE-627)ELV000729329 volume:111 year:2018 pages:177-179 extent:3 https://doi.org/10.1016/j.ypmed.2018.03.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.91 Psychiatrie Psychopathologie VZ AR 111 2018 177-179 3 |
| allfieldsSound |
10.1016/j.ypmed.2018.03.011 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica (DE-627)ELV042863112 (ELSEVIER)S0091-7435(18)30100-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.91 bkl Castle, Philip E. verfasserin aut Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. 2018transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. Wheeler, Cosette M. oth Campos, Nicole G. oth Sy, Stephen oth Burger, Emily A. oth Kim, Jane J. oth Enthalten in Elsevier Hamatani, Sayo ELSEVIER Impaired central coherence in patients with anorexia nervosa 2017 an international journal devoted to practice and theory Amsterdam (DE-627)ELV000729329 volume:111 year:2018 pages:177-179 extent:3 https://doi.org/10.1016/j.ypmed.2018.03.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.91 Psychiatrie Psychopathologie VZ AR 111 2018 177-179 3 |
| language |
English |
| source |
Enthalten in Impaired central coherence in patients with anorexia nervosa Amsterdam volume:111 year:2018 pages:177-179 extent:3 |
| sourceStr |
Enthalten in Impaired central coherence in patients with anorexia nervosa Amsterdam volume:111 year:2018 pages:177-179 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Psychiatrie Psychopathologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Impaired central coherence in patients with anorexia nervosa |
| authorswithroles_txt_mv |
Castle, Philip E. @@aut@@ Wheeler, Cosette M. @@oth@@ Campos, Nicole G. @@oth@@ Sy, Stephen @@oth@@ Burger, Emily A. @@oth@@ Kim, Jane J. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000729329 |
| dewey-sort |
3610 |
| id |
ELV042863112 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042863112</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002530.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ypmed.2018.03.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042863112</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-7435(18)30100-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.91</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castle, Philip E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wheeler, Cosette M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campos, Nicole G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sy, Stephen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Burger, Emily A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Jane J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamatani, Sayo ELSEVIER</subfield><subfield code="t">Impaired central coherence in patients with anorexia nervosa</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal devoted to practice and theory</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV000729329</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:111</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:177-179</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ypmed.2018.03.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.91</subfield><subfield code="j">Psychiatrie</subfield><subfield code="j">Psychopathologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">111</subfield><subfield code="j">2018</subfield><subfield code="h">177-179</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| author |
Castle, Philip E. |
| spellingShingle |
Castle, Philip E. ddc 610 bkl 44.91 Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| authorStr |
Castle, Philip E. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000729329 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.91 bkl Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| topic |
ddc 610 bkl 44.91 |
| topic_unstemmed |
ddc 610 bkl 44.91 |
| topic_browse |
ddc 610 bkl 44.91 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c m w cm cmw n g c ng ngc s s ss e a b ea eab j j k jj jjk |
| hierarchy_parent_title |
Impaired central coherence in patients with anorexia nervosa |
| hierarchy_parent_id |
ELV000729329 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Impaired central coherence in patients with anorexia nervosa |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000729329 |
| title |
Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| ctrlnum |
(DE-627)ELV042863112 (ELSEVIER)S0091-7435(18)30100-2 |
| title_full |
Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| author_sort |
Castle, Philip E. |
| journal |
Impaired central coherence in patients with anorexia nervosa |
| journalStr |
Impaired central coherence in patients with anorexia nervosa |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
177 |
| author_browse |
Castle, Philip E. |
| container_volume |
111 |
| physical |
3 |
| class |
610 VZ 44.91 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Castle, Philip E. |
| doi_str_mv |
10.1016/j.ypmed.2018.03.011 |
| dewey-full |
610 |
| title_sort |
inefficiencies of over-screening and under-screening for cervical cancer prevention in the u.s. |
| title_auth |
Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| abstract |
There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. |
| abstractGer |
There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. |
| abstract_unstemmed |
There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. |
| url |
https://doi.org/10.1016/j.ypmed.2018.03.011 |
| remote_bool |
true |
| author2 |
Wheeler, Cosette M. Campos, Nicole G. Sy, Stephen Burger, Emily A. Kim, Jane J. |
| author2Str |
Wheeler, Cosette M. Campos, Nicole G. Sy, Stephen Burger, Emily A. Kim, Jane J. |
| ppnlink |
ELV000729329 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.ypmed.2018.03.011 |
| up_date |
2024-07-06T17:18:30.791Z |
| _version_ |
1803850938626080768 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042863112</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002530.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ypmed.2018.03.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042863112</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-7435(18)30100-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.91</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castle, Philip E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wheeler, Cosette M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campos, Nicole G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sy, Stephen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Burger, Emily A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Jane J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamatani, Sayo ELSEVIER</subfield><subfield code="t">Impaired central coherence in patients with anorexia nervosa</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal devoted to practice and theory</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV000729329</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:111</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:177-179</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ypmed.2018.03.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.91</subfield><subfield code="j">Psychiatrie</subfield><subfield code="j">Psychopathologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">111</subfield><subfield code="j">2018</subfield><subfield code="h">177-179</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| score |
7.4004107 |